Toronto, ON – January 10th, 2026 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has executed an agreement with Østfold Hospital Trust of Norway.
“It was gratifying to be selected as the supplier to Østfold Hospital Trust following a lengthy diligence and negotiation process completed over the summer and fall of 2025. We continue to be incredibly impressed with the team’s success in both executing and publishing exceptional research into MDMA as a potential treatment for Major Depressive Disorder,” said Nicholas Kadysh, CEO, PharmAla Biotech. “We are excited and committed to help support them in their goal, and look forward to delivering investigational LaNeo MDMA to them to help support this exceptional work – and gratified that our previous establishment of a value chain across Europe will be helpful in the technical operations needed to make this delivery.”
The sales agreement contains both financial and data-sharing provisions. PharmAla will seek to ship its LaNeo MDMA Clinical Research Materials to Østfold Hospital Trust at the earliest opportunity, subject to customary regulatory approvals.
“PharmAla was selected after a competitive review of potential manufacturers”, said Tor-Morten Kvam at Østfold Hospital Trust. “Their demonstrated professionalism and understanding of the regulatory and scientific requirements for clinical research made them a strong partner for this study.”
Researchers like those at Østfold Hospital Trust can access a tool, offered at https://pharmala.ca/clinical-trials, which provides access to drug product quality information, which researchers can examine directly. PharmAla is confident that it can offer research customers rapid support to convert their clinical trial registrations and IRB approvals to the LaNeo MDMA Chemistry, Manufacturing and Control package.
PharmAla will consider discounts in favour of data sharing where appropriate. Qualified clinical researchers may contact sales@pharmala.ca.
PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.
Nicholas Kadysh, CEO
press@pharmala.ca